CEO Matthew Kapusta opened the call by emphasizing uniQure’s enduring focus on advancing gene therapies, highlighting "groundbreaking 3-year data from our Phase I/II study of AMT-130," which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results